-
How Breast Cancer Patients Metabolize Tamoxifen Affects Outcomes
Share this:
A new study confirms that a patient’s ability to metabolize the breast cancer drug tamoxifen affects the outcome of her treatment. Researchers at the Mayo Clinic Cancer Center and the Austrian Breast and Colorectal Cancer Study Group confirm that women with early breast cancer who are treated with tamoxifen and have genetic alterations in the liver enzyme CYP2D6 have a higher likelihood of cancer recurrence. Lead author Matthew Goetz, M.D., says,“Our findings confirm that in early breast cancer treated with tamoxifen, genetic alterations in CYP2D6 lead to a higher likelihood of recurrence and death.”
The study is published in the journal Clinical Cancer Research
Click here for news release
Sound bites with Dr. Goetz are available in the downloads above
Expert title for broadcast cg: Dr. Matthew Goetz, Mayo Clinic Oncologist
Share this:
Related articles
National Influenza Vaccination Week will be observed Dec. 4–8, which makes this a good time to learn more about the flu and why it's especially important ...
When David Elder’s back started to hurt in the fall of 2022, he thought his recurrent spasms had returned. But when medication didn’t help like ...
When Joanina Gicobi began her Ph.D. degree five years ago at Mayo Clinic Graduate School of Biomedical Sciences, she was interested in thinking creatively about ways ...